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Abstract
Background: Non-tuberculous mycobacteria (NTM) are ubiquitous in the environment and they infect mainly persons with
underlying pulmonary diseases but also previously healthy elderly women. Defects in host resistance that lead to
pulmonary infections by NTM are relatively unknown. A few genetic defects have been associated with both pulmonary and
disseminated mycobacterial infections. Rare disseminated NTM infections have been associated with genetic defects in T-
cell mediated immunity and in cytokine signaling in families. We investigated whether there was an association between
NTM infections and deficiencies of complement components C4A or C4B that are encoded by major histocompatibility
complex (MHC).
Methods: 50 adult patients with a positive NTM culture with symptoms and findings of a NTM disease were recruited.
Patients’ clinical history was collected and symptoms and clinical findings were categorized according to 2007 diagnostic
criteria of The American Thoracic Society (ATS). To investigate the deficiencies of complement, C4A and C4B gene copy
numbers and phenotype frequencies of the C4 allotypes were analyzed. Unselected, healthy, 149 Finnish adults were used
as controls.
Results: NTM patients had more often C4 deficiencies (C4A or C4B) than controls (36/50 [72%] vs 83/149 [56%], OR = 2.05,
95%CI = 1.019–4.105, p = 0.042). C4 deficiencies for female NTM patients were more common than for controls (29/36 [81%]
vs 55/100 [55%], OR = 3.39, 95% CI = 1.358–8.460, p = 0.007). C4 deficiences seemed not to be related to any specific
underlying disease or C4 phenotype.
Conclusions: C4 deficiency may be a risk factor for NTM infection in especially elderly female patients.
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Introduction
Non-tuberculous mycobacterial (NTM) infections have been
related to underlying pulmonary diseases [1,2,3]. In recent studies,
however, up to two-thirds of NTM infections were found in
patients without predisposing lung diseases with a predominance
of elderly female patients [4,5,6,7]. Host-related causal factors of
pulmonary and extra pulmonary NTM infections in elderly
immunocompetent patients are mostly unknown [8,9,10]. Recent-
ly, reduced nasal nitric oxide production, reduced ciliary beat
frequency and abnormal toll like receptor responses were observed
in pulmonary NTM patients [11]. Familial clustering and genetic
risk factors for pulmonary NTM diseases have been suggested in
earlier studies [12,13,14,15]. The rare disseminated NTM diseases
have been reported in the families with a few mutations in
interferon- c (INF-c) and interleukin (IL-12) signaling
[15,16,17,18,19]. However, these defects in INF-c/IL-12 produc-
tion have not been found among pulmonary NTM patients
[19,20]. Acquired neutralizing auto-antibodies against INF-c have
been associated with multiple opportunistic infections, which
include disseminated NTM [21]. Therefore, the pathogenesis of
the pulmonary NTM obviously differs from those of the
disseminated NTM infections. Clinically, the pulmonary NTM
patients are diagnosed late. Consequently, the patients will have
already developed structural defects by the time diagnosis is made
[10].
Genetic susceptibility to pulmonary tuberculosis has been
associated with major histocompatibility complex (MHC) class I,
II and III regions on chromosome 6p21.3 [19,22]. Complement
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genes C4 (C4A, C4B), C2, and FB are located in the MHC class III
region between the class I (HLA-A, -C, -B) and the class II (HLA-
DR, -DQ, -DP) [19,22]. Pulmonary tuberculosis has been
associated to human leukocyte antigen (HLA) class I and II genes
in several populations with variable and moderate susceptibilities
[23,24,25,26,27]. MHC complement genes C2, C4, and factor B
(FB), and C3 have been studied in an Indian population showing
increased frequencies of complete C4A deficiency, BF*FA and
C3*F in patients with pulmonary tuberculosis compared with
healthy individuals [22].
The complement system is involved both in innate and acquired
immune responses consisting of a triggered-enzyme cascade
activated by immunoglobulins, mainly by IgG1 [28]. Activated
complement proteins bind covalently to pathogens, thereby
opsonizing them prior to the antigen’s engulfment by macrophag-
es, which in turn bear the receptors for the complement factors
[28]. However, the capsular lipid layer of the mycobacteria makes
them resistant to the host’s defense mechanisms, and thus the
mycobacteria can evade phagocytosis and lysosomes [29]. The
Mycobacterium tuberculosis (MTB) survives and multiplies within
macrophages and adapt to the hostile environment [30,31].
Mycobacterium bovis (BCG) has been shown to activate all three
complement pathways and the important role of the INF-c
pathway in host defence has been revealed [20]. The defects of the
complement genes will produce quantitatively less active comple-
ment proteins, which will thus hamper the opsonization and
positive feedback of IL-12/IFN- c of the macrophages [30].
Possibly, the opportunistic NTM may also use this mechanism to
evade the host defense.
We evaluated the deficiencies of complement components C4A
and C4B in patients with a NTM infection. Patients were
evaluated according to American Thoracic Society (ATS) 2007
criteria [32]. We compared the frequencies of C4 deficiencies in
the NTM patients with those of the unselected healthy Finnish
adult controls. We found increased frequencies of C4 deficiencies
to be a plausible risk factor for NTM infection.
Materials and Methods
Study populations
In total, there were 257 patients with a NTM isolation in the
patient recruitment area of the study hospital during the study
period. These patients were admitted to the Division of Lung
Diseases or to the Division of Infectious Diseases, at Helsinki
University Central Hospital between August 2004 and December
2009 due to symptoms of a NTM disease. Out of admitted patients
we recruited 52 voluntary patients, aged over 18 years, who were
culture-positive for a non-tuberculous mycobacterial infection. 50
NTM patients gave their written informed consent after informa-
tion was given face-to-face. Two patients were excluded due to
missing consent. There were no cases with a family history of a
mycobacterial disease among the recruited patients. Peripheral
blood samples of 35 ml were drawn from patients for allotypic and
genetic analysis of complement C4 in an average within one month
of admission to hospital before any antimycobacterial therapy.
According to the study protocol patients who were pregnant,
handicapped, prisoners, under 18 years of age, conscripts and
patients with HIV or CVI (common variable immunodeficiency)
were excluded from the study. The control cohort (n=149)
consisted of healthy, voluntary blood donors, 100 females and 49
males, had been recruited in a health survey of the Helsinki region
[33]. The Ethics Committee of the Department of Medicine,
Hospital District of Helsinki and Uusimaa approved the study
protocol March 1, 2004.
Case definitions
The NTM infection patients were categorized according to
ATS criteria 2007 [32] in order to reveal how many fulfilled the
ATS diagnosis for NTM disease. According to these diagnostic
criteria, a patient should have NTM isolated in at least two sputum
cultures, or one positive culture from a bronchoscopic sample (by
lavage or by brush) or from a lung biopsy to fulfill the
microbiological criteria. One positive culture from a skin or
lymphatic tissue biopsy fulfilled the microbiological criteria for
extra pulmonary disease. Radiological criteria were fulfilled when
nodular or cavitary opacities were found on chest radiographs or
computer tomography (CT), or when bronchiectasis with multiple
small nodules were found by CT. The numbers of subsequent
positive mycobacterial smears and cultures and the site of
sampling were also recorded.
Demographic characteristics of the patients including age, sex,
and occupation, were obtained from the patient records. Each
patient’s previous medical history was reviewed, and concomitant
diseases were classified according to McCabe and Jackson [34] as
follows: (1) healthy, i.e. no other disease, (2) chronic nonfatal
disease, (3) ultimately fatal disease with an expected life expectancy
of 5 years maximum, and (4) rapidly fatal disease with expected
survival of no more than 6 months.
In particular, information on previous pulmonary diseases, such
as bronchiectasis, COPD, pulmonary fibrosis, prior tuberculosis,
asthma, pulmonary malignancies and pneumonias, were retrieved.
Signs, symptoms, laboratory findings and radiological examina-
tions were reviewed at the time of recruitment or closest +/26
months. Radiological findings on chest X-ray, CT and high-
resolution computed tomography (HRCT) were classified based
on the clinical radiologists statement as infiltrates, nodules, cavities
or bronchiectasis according to the ATS criteria 2007 [32]. The
anatomical localization of the findings for each lobe was recorded
separately or as diffuse findings in both lungs. Current (within 6
months of recruitment) immunosuppressive treatments were
reviewed.
All 50 NTM patients fulfilled the ATS 2007 criteria for
symptoms and all but one fulfilled the bacteriological criteria as
well. The sole exception was a male patient with pulmonary
cancer. That patient did not fulfill bacteriological criteria and he
had bilateral nodules in his lungs that could be classified as either
belonging to NTM or to the malignancy, which made fulfillment
of the radiological criteria uncertain. This patient presented with a
sputum smear positive finding, which included other NTM,
according to PCR, but the culture remained negative. The patient
died soon after without further examinations being made.
Radiological criteria were fulfilled for 29/44 (66%) with pulmo-
nary NTM. Fifteen patients 15/44 (34%) did not fulfill the
radiological criteria due to cancer or COPD findings without
nodules, cavities or bronchiectasis. However, all except one patient
repeatedly gave positive NTM sputum samples over the time of
recruitment (closest +/2 one year). All six patients with extra
pulmonary NTM fulfilled the ATS 2007 criteria.
Laboratory methods
All samples for mycobacterial staining except blood samples
were stained with auramine-O-fluorochrome dye and examined
microscopically for the presence of acid-fast bacilli (AFB). Cultures
that were positive for acid-fast bacilli were identified by DNA strip
assays (GenoType Mycobacterium CM/AS, Hain Lifescience,
Nehren, Germany). Mycobacterium avium complex (MAC), M. avium,
and Mycobacterium intracellulare were all classified as MAC.
The numbers of C4A and C4B genes and allotypes of C4A and
C4B proteins were determined in the HLA Laboratory, which is a
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division of the Transplantation Laboratory at the Haartman
Institute, University of Helsinki, as previously published [35]. The
HLA Laboratory has international EFI-accreditation (European
Federation for Immunogenetics). All samples were kept frozen at
270uC. CT insertion, a C4-silencing mutation, was reduced from
the amount of C4A genes. C4 deficiency was defined as the
presence of less than two copies of C4A or C4B.
Statistical methods
All statistical tests were performed using IBM SPSS statistics
software (version 20, NY). Differences in proportions between
groups were tested by the Chi-square test or by Fisher’s exact two-
tailed test, according to which was appropriate. Continuous
variables that were not normally distributed were transformed as
such by using logarithmic transformation. The continuous
variables were compared using the Student’s t-test. The Mantel-
Haenszel method and the Breslow-Day test were used to test the
homogeneity of the odds ratios between males and females. The
sample size calculation was based on the prevalence previously
reported 58% prevalence of C4 deficiency in healthy controls and
an assumption of C4 deficiency in 80% of NTM patients [33]. A
two group c2 test with a 0,05 two-sided significance level will have
80% power to detect the difference between these prevalences
(odds ratio of 2,90) resulted in sample sizes are of 47 NTM patients
and 141 healthy controls, respectively. P -values of ,0.05 were
considered statistically significant.
Results
Patient characteristics and mycobacterial strains
All NTM patients were of European descent. Forty-four patients
had pulmonary NTM infection whereas six patients had extra
pulmonary NTM infection. There was a clear female dominance
among the NTM patients (36/50 [72%], Table 1). Notably, the
NTM patients had a high incidence of ultimately or rapidly fatal
underlying diseases (McCabe classes III–IV, 18/50 [36%] and a
high incidence of bronchiectasis (15/50 [30%], Table 1).
MAC comprised 36/50 (72%) of all NTM isolations. Rapidly
growing mycobacteriua (M. fortuitum, M. chelonae, M. abscessus)
isolations accounted for 12% (6/50) isolations. Moreover, three
patients had M. malmoense and two patients had M. xenopi. One
patient had M. marinum and two patients other NTM. No patients
had concomitant NTM and M.tuberculosis (MTB) infections.
Complement analyses
C4 deficiency was more prevalent in the NTM patients than in
the healthy controls (36/50 [72%] vs 83/149 [56%], OR=2.05,
95% CI= 1.019–4.105, p = 0.042, Table 2). Deficiencies of C4A
and C4B were assessed individually but no statistically significant
differences between the NTM and healthy patients were found
(Table 2).
The majority of the NTM patients were female; consequently
we assessed the C4 deficiencies in females only. We compared
females in the healthy control group with females in the NTM
patient group (Table 3). Deficiency of C4 occurred more often in
the female NTM patients than in the healthy female controls (29/
36 [81%] vs 55/100 [55%], OR=3.390, 95% CI= 1.358–8.460,
p = 0.007, Table 3). There was a tendency for more common
deficiency of both C4B and C4A in the females NTM patients as
compared to female controls but these differences did not reach
statistical significance (Table 3). In the subgroup analyses no
difference in C4 deficiency was observed between male NTM and
male control patients (7/14 [50%] vs 28/49 [57%], OR=0.75,
95% CI=0.23–2.47, p = 0.045) The subgroup analyses were
justified as the Breslow-Day test found evidence of interaction
between sex and infection (NTM vs. Healthy) with respect to type
of deficiency (p= 0.108 for C4B,2 and p= 0.045 for C4Aor
C4B,2). However, the number of men was too low for reliable
analysis (n = 14 in NTM and n= 49 in H).
Next, we specifically investigated whether a C4 deficiency was
associated with different patient characteristics of the NTM
patients (Table 4). Either C4A or C4B deficiency was observed in
31/44 (70%) of the NTM patients with the pulmonary NTM
infection. A C4 deficiency was found in 22/29 (76%) of those
pulmonary NTM patients who met all ATS 2007 criteria. All five
patients with a cutaneous NTM infection met the ATS 2007
criteria and they all had C4B deficiency. C4 deficiency was found
in 67% of the patients who did not meet the radiological criteria,
but who repeatedly gave a positive NTM sputum culture (Table 4).
There were some differences in the phenotype frequencies of
the C4 allotypes between the patient groups (Table 5). The A3, Q0
allotype was found in (12/50, 24%) of the NTM patients, which
Table 1. Characteristics,underlying diseases and laboratory
findings of 50 patients with a non-tuberculous mycobacteria
(NTM).
NTM
n=50
n (%)
Age median (IQR) yr 65 (17)
Female 36 (72)
Pulmonary mycobacterial infection 44 (88)
Mycobacterial infection in lymph nodes 1 (2)
Cutaneous mycobacterial infection 5 (10)
Underlying diseasesa
Healthy or non-fatal diseases(1–2) 32 (64)
Ultimately or rapidly fatal diseases(3–4) 18 (36)
Underlying pulmonary diseases
Bronchiectasis 15 (30)
COPD 13 (26)
Prior tuberculosis 3 (6)
Asbestosis 2 (4)
Asthma 4 (8)
Pulmonary or other malignancy 6 (12)
No previous pulmonary diseases 16 (32)
Rheumatoid arthritis 8 (16)
Other autoimmune disease 3 (6)
Never smokers 27 (54)
Current or ex-smokers 23 (46)
Laboratory finfindings
ESR median (IQR) mm/h 18.5 (30)
CRP median (IQR) mg/l 6.5 (16)
Values are expressed as number (%) of patients with valid information unless
otherwise stated.
aUnderlying diseases classified according to the criteria of the McCabe
classification:
1)healthy i.e. no other diseases.
2)non-fatal chronic diseases.
3)ultimately fatal diseases with expected life expectancy of maximally 5 years.
4)rapidly fatal diseases with expected survival for no more than 6 months.
doi:10.1371/journal.pone.0091450.t001
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reflected the increased frequency of C4A deficiency in NTM
patients. The C4 allotype, A3, 3 was less common in the NTM
patients (11/50, 22%) than in the healthy controls (58/149 [39%],
p = 0.030, Table 5). The allotype B1, 2 was found in only 6% of
the NTM patients (3/50) but in 20% of the healthy controls (30/
149), p = 0.020, Table 5).
Discussion
Our study suggests that deficiency of C4 might have a role for
susceptibility to a NTM infection. This finding is consistent with
previous studies, which had revealed increased frequencies of
complement C4A deficiency in mycobacterial infections, especially
in patients with pulmonary MTB [22,36]. To the best of our
knowledge, ours is the first study to report C4 deficiency at gene
level in NTM infected patients. We observed that the deficiencies
of C4 in NTM infected patients were significantly more common
(72%) than in the healthy controls (56%). Furthermore, our study
pinpointed the high 81% frequency of the C4 deficiency among
female NTM patients, suggesting that C4 deficiency might be a
risk factor for this specific patient group for NTM infection.
The polymorphisms of the complement and its receptor genes
have been associated as a susceptibility factor for pulmonary
tuberculosis [19]. The defects of the complement will lead to
production of quantitatively less active complement proteins,
which might thus hamper the opsonization and phagosytosis [28].
The thick capsular lipid layer of the opportunistic NTM may be
one important mechanism how NTM evade the host defense [29].
Moreover it has been hypothesized, that complement proteins are
involved in a mechanism through which mycobacteria enter the
cell and may thereby evade the adaptive immune response [30].
C4 deficiency found in our study might not only limit the
complement activation and interfere opsonisation but also affect
the positive feedback of IL-12/IFN- c in macrophages.
Complement C4 deficiencies are common. In European decent
North Americans, 13% lack one of the two C4A alleles and 18%
are deficient of one of the two C4B alleles [37]. C4 deficiencies are
even more common in the Finnish population. In Finland, 17%
lack one of the two C4A alleles and 38% lack one of the two C4B
alleles [33]. In our study the A3, Q0 allotype reflecting C4A
deficiency, had an increased occurrence among the female NTM
patients. Deficiency in C4A has previously been associated to
several autoimmune diseases and in adults with upper respiratory
infections and pulmonary tuberculosis [22,33]. In the recent
report, C4A deficiency was suggested to predispose children and
adolescents to recurrent respiratory infections. Also in this report
girls predominated in patients with C4A deficiency [38] corrob-
orating our results in NTM. Other studies have reported
associations between C4B deficiency and another mycobacterial
disease, leprosy [39]. In our study all the five patients with
cutaneous NTM infection had C4B deficiency.
The C4 deficiencies are associated with certain HLA alleles and
are inherited together as haplotypes. The haplotype and allele
frequencies differ significantly between populations and ethnicities
[22,23,24,37]. Yet, a C4 deficiency might serve as a surrogate or a
marker of an immunological deficit that is associated with the
NTM infection because of the high linkage disequilibrium between
genes of the MHC haplotypes. The analyses of the whole MHC
haplotypes with landmark markers of several genes including
complement C4 and TNF in addition to the conventional HLA
alleles are highly warranted in MHC associated disease studies
such as NTM in different ethnicities.
NTM infections without previous underlying diseases usually
have a high prevalence especially in elderly women [2,3,8,40,41].
This is probably due to influence of aging on the immune system,
which might manifest in both cellular and humoral immune
responses. Those changes might predispose postmenopausal
women to autoimmune diseases and the NTM infections
[13,42]. Moreover, the average age of diagnosis of the NTM
infection in our present study was 65 years and most of the patients
(64%) were otherwise healthy postmenopausal women. Elderly,
slender female patients with the NTM infection often have
bronchiectasis [3,10,43]. In this study 73% of the NTM patients
with bronchiectasis had a deficiency in C4. Our results suggest that
the C4 deficiency and bronchiectasis might be one predisposing
factor for pulmonary NTM infection especially in elderly women.
Although our patient material was small the advantage of this
study was that NTM patients were of European descent without
different ethnicities. Namely, the susceptibility to mycobacteria
disease is variable among different ethnic groups (23, 24, 25, 26).
Our results must be regarded as preliminary due to small
patient material although a C4 deficiency was statistically
significantly more common in NTM patients as compared to
Table 2. Genotypic C4 deficiencies in patients with non-
tuberculous mycobacteria (NTM) and in healthy control
population (H).
NTM H NTM vs H
n=50 n=149
Type of
deficiency n (%) n (%) OR (95% CI) pa
C4A,2 13 (26) 24 (16) 1.83 (0.85–3.95) 0.120
C4B,2 25 (50) 61 (41) 1.44 (0.76–2.75) 0.263
C4A or C4B,2 36b (72) 83 (56) 2.05 (1.019–4.105) 0.042
C4,4 22 (44) 56 (38) 1.30 (0.68–2.50) 0.421
Values are expressed as number (%) of patients, unless otherwise stated.
Abbreviations:
OR =odds ratio,
CI = confidence interval.
ap values for differences between groups.
bTwo patients had both C4A,2 and C4B,2 deficiency, one patient had a total
C4A deficiency.
doi:10.1371/journal.pone.0091450.t002
Table 3. Type of genotypic C4 deficiency in female non-
tuberculous mycobacteria (NTM) patients compared with
healthy female control population (H).
NTM female H female NTM female vs H female
n=36 n=100
Type of
deficiency n (%) n (%) OR (95% CI) pa
C4A,2 11b (31) 17 (17) 2.148 (0.891–5.181) 0.085
C4B,2 20 (56) 38 (38) 2.04(0.94–4.41) 0.068
C4A or C4B,2 29c (81) 55 (55) 3.390 (1.358–8.460) 0.007
Values are expressed as number (%) of patients, unless otherwise stated.
Abbreviations:
OR =odds ratio,
CI = confidence interval.
ap values for differences between groups.
bOne female patient had a total C4A deficiency.
cTwo female patients had both C4A,2 and C4B,2 deficiency.
doi:10.1371/journal.pone.0091450.t003
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healthy controls and even more clearly in female patients. On the
other hand, the small sample size may have resulted that some
clinically important (OR$2.00) differences failed to reach
significance. In the subgroup of women, the odds ratios of 2.15
and 2.04 failed to reach significance (Table 3). The power to find a
significant difference in these analyses was only 33% and 37%,
respectively and the required number of NTM patients were 102
and 87 subjects, respectively (with 0.05 two-sided significance
level, 80% power and with unequal sample sizes; 1 patient:3
controls). The required total number of women was then 407 and
346 to observe a real difference in C4A and C4B in female
populations, respectively. Due to the sample size limitations, the
results of the subgroup analyses should be regarded as tentative.
The environmental risk factors with distinct associations to
NTM disease are controversial [44,45] and environmental effects
together with genetic default should be focused on more
specifically when studying pulmonary NTM disease. In this study
more than half of the NTM patients (27/50) had never smoked
and 25 of these non-smokers were female. There were 23 current
or ex-smokers, but only 11 of them were female.
In conclusion, our study indicates that Finnish NTM patients
had significantly more often C4 deficiencies than the healthy
control subjects. The findings of this study suggest that both a
deficiency of complement C4 and bronchiectasis in healthy females
might have a role as risk factors for pulmonary NTM infections.
Due to the sample size limitations, the results of this preliminary
study should be regarded as tentative. Further investigation with a
larger study to confirm the current findings is obvious.
Acknowledgments
The skillful technical assistance of the laboratory assistants is greatly
appreciated and acknowledged.
Author Contributions
Conceived and designed the experiments: HK M-LL MS PT SM VV AJ.
Performed the experiments: HK M-LL JE. Analyzed the data: HK M-LL
RP MS SM TP VV AJ. Contributed reagents/materials/analysis tools:
M-LL RP JE. Wrote the paper: HK M-LL RP MS PT JE SM VV AJ.
References
1. Maliwan N, Zvetina JR (2005) Clinical features and follow up of 302 patients
with Mycobacterium kansasii pulmonary infection: a 50 year experience.
Postgrad Med J 81: 530–533.
2. Field SK, Fisher D, Cowie RL (2004) Mycobacterium avium complex
pulmonary disease in patients without HIV infection. Chest 126: 566–581.
3. Piersimoni C, Scarparo C (2008) Pulmonary infections associated with
nontuberculous mycobacteria in immunocompetent patients. Lancet Infect Dis
8: 323–333.
4. Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL (2009) Non-
tuberculous mycobacterial disease prevalence and risk factors: a changing
epidemiology. Clin Infect Dis 49: 124–129.
5. Thomson RM (2010) Changing epidemiology of pulmonary nontuberculous
mycobacteria infections. Emerg Infect Dis 16: 1576–1583.
6. Iseman MD, Marras TK (2008) The Importance of Nontuberculous
Mycobacterial Lung Diseas. Am J Respir Crit Care Med 178: 999–1001.
7. Kotilainen H, Valtonen V, Tukiainen P, Poussa T, Eskola J, et al. (2010) Clinical
symptoms and survival in non-smoking and smoking HIV-negative patients with
non-tuberculous mycobacterial isolation. Scand J Infect Dis 43: 188–196.
8. Prince DS, Peterson DD, Steiner RM, Gottlieb JE, Scott R, et al. (1989)
Infection with Mycobacterium avium complex in patients without predisposing
conditions. N Engl J Med 321:863–868.
9. Iseman MD, Buschman DL, Ackerson LM (1991) Pectus excavatum and
scoliosis: thoracic anomalies associated with pulmonary disease caused by
Mycobacterium avium complex. Am Rev Respir Dis 144: 914–916.
10. Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, et al. (2008)
Pulmonary Nontuberculous Mycobacterial Disease Prospective Study of a
Distinct Preexisting Syndrome. Am J Respir Crit Care Med 178: 1066–1074.
11. Fowler CJ, Olivier KN, Leung JM, Smith CC, Huth AG, et al. (2013) Abnormal
Nasal Nitric Oxide Production, Ciliary Beat Frequency, and Toll-like Receptor
Response in Pulmonary Nontuberculous Mycobacterial Disease Epithelium.
Am J Respir Crit Care Med 187: 1374–1381.
12. Colombo RE, Hill SC, Claypool RJ, Holland SM, Olivier KN (2010) Familial
Clustering of Pulmonary Nontuberculous Mycobacterial Disease. Chest 137:
629–634.
13. Kartalilja M, Fantuzzi G, Thomas J, Strand MJ, Bai X, et al. (2013) Patients
with nontuberculous mycobacterial lung disease exhibit unique body and
immune phenotypes. Am J Respir Crit Care Med 187: 197–205.
14. Koh WJ, Kwon OJ, Kim EJ, Lee KS, Ki CS, et al. (2005) NRAMP1 gene
polymorphism and susceptibility to NTM lung diseases. Chest 128: 94–101.
15. Casanova J-L, Abel L (2002) Genetic dissection of immunity to mycobacteria:
The Human Model. Annu Rev Immunol 20: 581–620.
16. Dorman SE, Holland SM (2000) Interferon gamma and interleukin-12 pathway
defects and human disease. Cytokine Growth Factor Rev 11: 321–333.
17. Guide SV, Holland SM (2002) Host susceptibility factors in mycobacterial
infection: Genetics and bodymorphotype. Infect Dis Clin North Am 16: 163–
186.
18. Haverkamp MH, van Dissel JT, Holland SM (2006) Human host genetic factors
in nontuberculous mycobacterial infection: lessons from single gene disorders
affecting innate and adaptive immunity and lessons from molecular defects in
interferon-c-dependent signaling. Microbes Infect 8: 1157–1166.
19. Fernando SL, Britton WJ (2006) Genetic susceptibility to mycobacterial disease
in humans. Rev. Immunol Cell Biol 84: 125–137.
20. Holland SM (2001) Nontuberculous Mycobacteria. Am J Med Sci 321: 49–55.
21. Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul
S, et al. (2012) Adult-Onset Immuno deficiency in Thailand and Taiwan.
N Engl J Med 367: 725–734.
22. Senbagavalli P, Kumar N, Kaur G, Mehra NK, Geetha C, et al. (2011) Major
histocompatibility complex class III (C2, C4, factor B) and C3 gene variants in
patients with pulmonary tuberculosis. Hum Immunol 72: 173–178.
23. Yuliwulandari R, Sachrowardi Q, Nakajima H, Kashiwase K, Hirayasuet K,
et al. (2010) Association of HLA-A, -B, and -DRB1 with pulmonary tuberculosis
in western Javanese Indonesia. Hum Immunol 71: 697–701.
Table 5. The most common C4 phenotypes in patients
infected with a non-tuberculous mycobacteria (NTM) and
Healthy group (H).
NTM H pb
n=50a n=149
n (%) n (%)
C4A phenotypec
3 12 (24) 21 (14) 0.103
3,2 3 (6) 9 (6) 1.000d
3,3 11 (22) 58 (39) 0.030
3,3,2 8 (16) 18 (12) 0.477
3,3,3 7 (14) 17 (11) 0.626
C4B phenotype
0 6 (12) 15 (10) 0.700
1 15 (30) 37 (25) 0.464
1,1 16 (32) 52 (35) 0.708
1,2 3 (6) 30 (20) 0.020
1,3 2 (4) 3 (2) 0.601d
2 3 (6) 6 (4) 0.694d
2,2 0 (0) 5 (3) 0.333d
aValues are expressed as numbers (%) of patients with valid information unless
otherwise stated.
bp Chi-squared test.
cOne patient with C4A total deficiency.
dFisher ’ s exact test.
doi:10.1371/journal.pone.0091450.t005
Complement C4 Deficiency - A Plausible Risk Factor for NTM
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e91450
